Current Edition

Biopharma

Roche recalls new eye therapy Susvimo on leakage fears, aims for market return ‘within a year or so’

Just as doctors were starting to cozy up to Roche and Genentech’s new eye drug delivery therapy, the companies are pulling the product from U.S. …

Continue Reading →
Biopharma

Love Pharma moves to buy transdermal opioid-use disorder player

Love Pharma has struck a deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering …

Continue Reading →
biopharmaceutical

Bankrupt Zosano sells intradermal delivery tech to Emergex Vaccines

The unraveling of Zosano Pharma has led to a drug delivery deal. With the company filing for bankruptcy in the wake of its rejection by …

Continue Reading →
biopharmaceutical

Chemotherapy drug derived from fungus shows promise

Oxford University researchers have collaborated with biopharmaceutical company NuCana to assess a novel chemotherapy drug derived from a fungus. The results of a study published …

Continue Reading →
AiPharma

AiPharma forms alliance with Appili Therapeutics

Private biopharmaceutical research, development, and commercialisation company, AiPharma, has announced a strategic alliance with biopharmaceutical company Appili Therapeutics Inc (Appili), to advance the global development …

Continue Reading →
biopharmaceutical

At the Forefront of Innovative Therapeutic Excellence Since 2006

Pharmaceutical and Biopharmaceutical sciences continue to find new applications, new modalities and a new class of compounds that can improve life expectancy and standards of …

Continue Reading →
AMR

The BIA welcomes the release of the AMR Industry Alliance’s first progress report

The BIA today welcomes the release of the AMR Industry Alliance’s first progress report assessing the action being taken to tackle antimicrobial resistance. The AMR Industry Alliance is …

Continue Reading →
biopharmaceutical

Phillips-Medisize Creates a Manufacturing Center of Excellence for Connected Health and Drug Delivery Devices

Phillips-Medisize, a Molex company, announces its initial investment to expand the capabilities of the 380,000 square foot Molex Little Rock facility to include a FDA …

Continue Reading →
allogeneic

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →
antibiotic

New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance

In 2017, the collective fight to combat antimicrobial resistance (AMR) has experienced a new upswing. Following the eye-opening report of British economist Lord Jim O’Neill, …

Continue Reading →